Clinical Trial Update: Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) [Phase 3]

View source ↗

Summary

Phase 3 trial results show efficacy of Secukinumab in active psoriatic arthritis at 24 weeks with long-term safety and tolerability data up to 2 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (Cosentyx) (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-02-04